The Spectrum of IPF: Making a Differential Diagnosis and Guiding Treatment

Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease. Despite advances in the management of IPF and frequent interactions with varying members of the multidisciplinary management team, patients with IPF report frustrations and significant emotional consequences of their disease. Clinicians involved in the care of patients with IPF require education on rapid advances in pharmacologic and nonpharmacologic approaches to provide evidence-based care that helps patients live longer and experience improved quality of life. This educational activity consists of two, 30-minute digital classroom activities to engage clinicians and ensure an effective educational activity. A patient education activity has been developed as well to help bridge the communication gap between clinicians and patients, while providing an educational resource specific for the patient and caregiver.

Intended Audience 

Pulmonologists, respiratory nurses, respiratory therapists, and other clinicians interested in treatment advances for patients with IPF

Educational Objectives

  • Discuss the impact of IPF on patient quality of life over the disease course
  • Describe benefits of a multidisciplinary approach over the course of IPF

FACULTY

Kevin R. Flaherty, MD, MS
Professor of Medicine
Pulmonary/Critical Care
University of Michigan
Ann Arbor, MI

Imre Noth, MD
Professor of Medicine
Director, Bronchoscopy
Director, Interstitial Lung Disease Program
The University of Chicago Medicine
Chicago, IL

Amy L. Olson, MD, MSPH
Assistant Professor
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Provided by

These activities are supported by educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.